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Non-invasive ventilation (NIV) is occasionally used for management of acute respiratory failure in a do-not-intubate (DNI)
patient, when conventional oxygen administration or high-flow nasal cannula fail to improve respiratory distress. In such
situations, the duration of NIV may be prolonged and cause complications due to the oro-nasal mask. The helmet can be an
alternative interface to the oro-nasal mask for improving tolerability and reducing complications. Although the efficacy of
helmet NIV has been demonstrated in patients with acute respiratory distress syndrome, the utility of helmet NIV in DNI pa-
tients has not been discussed. We present the case of a DNI patient with acute respiratory failure, in which helmet NIV was
used instead of the conventional oro-nasal mask. Helmet NIV proved effective in preventing pressure -induced skin compli-
cations associated with oro-nasal mask NIV and relieved discomfort in this patient. Furthermore, the patient’s communication
ability was retained, thereby respecting the wish of the patient and his family.
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Introduction
Non-invasive ventilation (NIV) is occasionally used for
management of acute respiratory failure in a do-not-
intubate (DNI) patient, when conventional oxygen ad-
ministration or high-flow nasal cannula (HFNC) fail to
improve respiratory status. In such situations, the dura-
tion of NIV is prolonged and problems caused by the
commonly used oro-nasal mask such as skin erosion of
the nasal dorsum complicate the continuation of NIV.
The helmet can be an alternative to the oro-nasal mask
for improving tolerability and reducing complications.
Although the efficacy of helmet NIV has been demon-
strated in patients with acute respiratory distress syn-
drome (ARDS),
１-３
the usefulness of helmet NIV in DNI
patients is unknown. We present the case of a DNI pa-
tient with acute respiratory failure, in whom helmet NIV
was used, after a complication with oro-nasal mask venti-
lation.
Case Presentation
A 72-year-old man with end-stage renal disease due to
diabetes mellitus presented with hallux gangrene and os-
teomyelitis, and was admitted in our hospital for surgical
management. He underwent uneventful amputation of the
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Figure　1　Supine chest X-ray (CXR, left) and computed tomography (CT, right) taken on re-admis-
sion to the intensive care unit. CXR shows diffuse ground-glass opacity, blunted border of diaphragm, 
and cardiomegaly. CT also shows diffuse ground-glass opacity, indicating recurrence of pneumonia 
and pulmonary edema.
Figure　2　A skin erosion of the nasal dorsum, which developed 
during the first admission to the intensive care unit (upper). Hel-
met non-invasive ventilation (StarMed CaStar R, Intersurgical,
Italy, lower).
right great toe. On the 16th postoperative day, he began
complaining of shortness of breath due to hypoxia, and
was transferred to our intensive care unit (ICU) after NIV
(Respironics V60, Philips Healthcare, The Netherlands)
support was initiated. Chest X-ray (CXR) and computed
tomography (CT) revealed diffuse ground-glass opacity
and consolidation. The patient was diagnosed with pneu-
monia and pulmonary edema. Although respiratory man-
agement by endotracheal intubation was recommended in
view of the need for long-term and effective respiratory
support, the patient and his family clearly declined the
procedure. Therefore, NIV (S/T mode, FIO2 0.5, IPAP 10
cmH2O, EPAP 6 cmH2O) was continued. Fortunately, his
respiratory status improved gradually with antibiotics and
haemodialysis; consequently, he was able to wean from
NIV. He was discharged from the ICU on the 10th day.
However, the patient was re-admitted to the ICU on
the 12th day after discharge due to relapse of hypoxia.
CXR and CT revealed diffuse ground-glass opacity (Fig-
ure 1). Although NIV using an oro-nasal mask was initi-
ated immediately after re-admission, pain caused by skin
erosion of the nasal dorsum, which had developed during
the previous treatment, made continuation of ventilation
impossible (Figure 2, upper). The patient also strongly
complained about the discomfort caused by tight fixation
of the headband. In spite of the relatively low degree of
support provided by the ventilator, continuation of ther-
apy was essential due to quick desaturation on removal
of the mask. As a result of the discussion of the treatment
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strategy at a multidisciplinary conference, the interface of
NIV was changed from oro-nasal mask to helmet
(StarMed CaStar R, Intersurgical, Italy) on the third ICU
day (Figure 2, lower ) . The helmet relieved the pain
caused by the oro-nasal mask, and facilitated continu-
ation of ventilation. Although the patient complained of
noise and dry mouth, this did not pose a problem for the
continuation of helmet NIV. Dexmedetomidine, a
sedative-analgesic agent, was administered only at night.
Hypercapnia did not occur during helmet NIV. The pa-
tient was able to wean from NIV using HFNC. He was
discharged from the ICU after 10 days. However, he died
due to progression of hypoxia without re-admission to
the ICU. The patient’s family was sincerely content to
have been able to communicate with him until the end of
his life owing to a treatment which was in line with his
wishes.
Discussion
In recent times, NIV has been used frequently in DNI pa-
tients with acute respiratory failure as a last resort. Re-
portedly, the percentage of DNI patients receiving total
NIV therapy is from 9.4 to 18.9%.
４，５
Although currently,
NIV plays a major role in respiratory management, there
are many complications in its long-term use, despite
maintenance of good respiratory support. The incidence
of complications has been reported as 10-20%.
４-６
Among
the complications, discomfort and pain due to pressure of
the mask are serious problems that may hinder NIV ther-
apy. Therefore, the helmet interface was introduced to
overcome the problems associated with use of the oro-
nasal mask.
Helmet interface of NIV has some benefits and draw-
backs compared to the conventional oro-nasal mask. The
benefits include no direct skin compression, ease of com-
munication, good visual field of the patient, easy man-
agement, reduction of leakage, and application of ade-
quate positive pressure.
７，８
These benefits could contribute
to favourable results in patients who require long-term
ventilatory support. However, the drawbacks are re-
breathing through large volume of air within helmet,
patient-ventilator asynchrony by high compliance of hel-
met, air inflow noise, and high cost.
９，１０
Compared to face mask NIV, the use of helmet NIV in
patients with ARDS has been reported to reduce the rate
of tracheal intubation, 90-day mortality, duration of hos-
pitalisation, and the prevalence of ICU-acquired weak-
ness and delirium.
１，２
Furthermore, helmet NIV facilitated
early mobilisation and contributed to shorter hospitalisa-
tion.
２
Although there are limited reports on the application of
helmet NIV in DNI patients, given that it is efficient in
patients with ARDS, it has been suggested that this pro-
cedure can extend the tolerable duration of ventilation,
and contribute to maintenance of the patient’s quality of
life. In our opinion, helmet NIV is an acceptable proce-
dure considering the prevention of further complications
and maintenance of good communication in the patient.
In case of failure of NIV due to the above complications,
palliative therapy without ventilation might have been re-
quired.
１１
However, in retrospect, continuation of helmet NIV in
the present case could be controversial, as the patient
may be considered to be in the end-of-life phase. Pro-
longing the terminal stage of the patient might seem un-
necessary, and the medical expenses would increase, as
the NIV helmet is expensive (helmet, JPY29,800; oro-
nasal mask, JPY12,000-26,000). In this patient, pulmo-
nary edema, a good indication for ventilatory support,
might have been the cause of hypoxia, which encouraged
the use of NIV even in a DNI patient. In addition, the pa-
tient and his family strongly desired recovery from respi-
ratory failure without the use of invasive mechanical ven-
tilation such as tracheal intubation. Generally, when such
patients become intolerant of oro-nasal mask NIV, NIV
should be discontinued and changed to palliative care us-
ing narcotics to relieve dyspnea.
１１
However, given that
the transition to palliative care may have been difficult
for him to accept, helmet NIV might be a good option for
respecting the wish of the patient and his family.
Conclusion
In a DNI patient with acute respiratory failure, helmet
NIV was effective in preventing complications associated
with mask ventilation, relieving discomfort, and provid-
ing continual NIV, thereby respecting the patient’s and
family’s wishes. Although helmet NIV was able to fulfil
the family’s demands, unnecessary prolongation of the
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terminal stage of a patient with NIV should be avoided.
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